about
Targeting autophagy in cancer management - strategies and developmentsTherapeutic options for management of endometrial hyperplasiaA phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.The pro-inflammatory effect of obesity on high grade serous ovarian cancer.Sensitization of cervical cancer cell lines to low-dose radiation by retinoic acid does not require functional p53.Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluA phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.Modeling effects of diabetes and obesity co-morbidities in endometrial cancer development and progression.Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2.Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures.Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of Sheta2 After Vaginal Administration To MiceChemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience researchNovel ovarian cancer maintenance therapy targeted at mortalin and mutant p53Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and PalbociclibPreclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer
P50
Q26782468-D520448F-4756-4A99-B4C3-447CBCB46F96Q26783569-87EF5691-3BDF-4A52-BC16-82E1D0FA328AQ34781699-5A8BF27A-CE73-403B-805F-A238293A31BEQ38288739-96052C39-F1F7-4694-B929-23C10BF2EBBDQ38841214-FBDB4BEE-B920-406C-9285-DCF840FC516CQ40442737-4856FA33-7665-4FD9-8C47-5CE316E31159Q42905560-A26CFA1C-8706-4A23-8087-83556503C73CQ44777739-CA5D10B3-CCB1-419A-9FA6-700FDAEA6AE2Q46035501-72645320-CDAA-4056-B6D2-4474A0DE4B37Q47186214-7830ED5A-884F-4788-95A0-70C773CDDFC5Q50857012-34BABC12-FED9-4EEA-BB57-C7FEC64D1685Q52381624-5157018D-12C3-4063-9D72-4451D9423A65Q52638223-06936953-249D-4A5A-8B54-462816BD4DF6Q53072832-2033F9B3-910B-4FA7-A9ED-6A548233E812Q54379484-2D06BB9C-462B-492C-BA19-C0847EE6E964Q57160181-6578720D-F9EA-4DD3-8D8A-C8A0C68CA726Q91628100-B6F99683-C3C2-4B47-A096-BF5AC996A877Q92034436-02067ADD-BF5C-4BD1-87A2-4B687EB51619Q95326707-A88A5E44-CB29-4DEC-ACAB-7E772A04969CQ95654823-AD4AADD5-FD5F-4628-A65E-AD50324D42A4
P50
description
researcher ORCID ID = 0000-0001-7606-8245
@en
name
Doris M Benbrook
@ast
Doris M Benbrook
@en
Doris M Benbrook
@nl
type
label
Doris M Benbrook
@ast
Doris M Benbrook
@en
Doris M Benbrook
@nl
prefLabel
Doris M Benbrook
@ast
Doris M Benbrook
@en
Doris M Benbrook
@nl
P31
P496
0000-0001-7606-8245